Übersicht – Möglichkeiten der molekularen Diagnostik von Nierenzelltumoren

• Literatur

• 1 Sanjmyatav J, Hauke S, Gajda M et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Europ Urol 2013; 64: 689-691
• 2 Chyhrai A, Sanjmyatav J, Gajda M et al. Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol 2010; 28: 269-274
• 3 Youssef YM, White NM, Grigull J et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Europ Urol 2011; 59: 721-730
• 4 Tolson J, Bogumil R, Brunst E et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 2004; 84: 845-856
• 5 Monzon FA, Alvarez K, Peterson L et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Path 2011; 24: 1470-1479
• 6 Klatte T, Rao PN, de Martino M et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27: 746-753
• 7 Sanjmyatav J, Junker K, Matthes S et al. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. J Urol 2011; 186: 2078-2083
• 8 Heinzelmann J, Henning B, Sanjmyatav J et al. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011; 29: 367-373
• 9 Wu X, Weng L, Li X et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PloS one 2012; 7: e35661
• 10 Slaby O, Redova M, Poprach A et al. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chrom Canc 2012; 51: 707-716
• 11 Hildebrandt MA, Gu J, Lin J et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728
• 12 Teixeira AL, Ferreira M, Silva J et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tum Biol 2013;
• 13 Hauser S, Wulfken LM, Holdenrieder S et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3 p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidem 2012; 36: 391-394
• 14 Redova M, Poprach A, Nekvindova J et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012; 10: 55
• 15 Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-49
• 16 Hakimi AA, Ostrovnaya I Reva Bet al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19: 3259-3267
• 17 Kapur P, Pena-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14: 159-167
• 18 Sato Y, Yoshizato T, Shiraishi Y et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature Gen 2013; 45: 860-867
• 19 Klatte T, Seligson DB, LaRochelle J et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol 2009; 18: 894-900
• 20 Eichelberg C, Chun FK, Bedke J et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2013; 132: 2948-2955
• 21 Parker AS, Leibovich BC, Lohse CM et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115: 2092-2103 Ch. D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Gen Cancer 2007; 5: 379–385
• 22 Nishikawa M, Miyake H, Harada K et al. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Med Oncol 2014; 31: 792
• 23 Prior C, Perez-Gracia JL et al. Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PloS one 2014; 9: e86263
• 24 Alqurashi N, Hashimi SM, Wei MQ. Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int L Mol Sci 2013; 14: 3874-3900
• 25 Garcia-Donas J, Esteban E, Leandro-Garcia LJ et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 2011; 12: 1143-1150
• 26 van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17: 620-629
• 27 Xu CF, Bing NX, Ball HA et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011; 29: 2557-2564
• 28 Gamez-Pozo A, Anton-Aparicio LM, Bayona C et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012; 14: 1144-1152